Pros and Cons of Genus plc in the next few years
Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
B****
?
G***** c******* t* c**********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Genus plc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Genus plc | 0.000% | -6.250% | -13.669% | 2.564% | -18.367% | -13.731% | -60.331% |
| Ligand Pharmaceuticals | 3.770% | 8.000% | 14.894% | 127.368% | 30.120% | 208.571% | 121.903% |
| United Therapeutics | 0.590% | 1.616% | -1.709% | 91.163% | 10.367% | 121.617% | 234.468% |
| Ionis Pharmaceuticals Inc. | 0.060% | 1.307% | -1.089% | 97.085% | -6.474% | 67.970% | 102.485% |
Comments
Genus (OTCMKTS:GENSF) had its "buy" rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft.
Show more
Ratings data for GENSF provided by MarketBeat

